Meeting
2024 ASCO Annual Meeting
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.
Authors
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, NY
Sherry Shen , Anton Safonov , Maria Bromberg , Yuan Chen , Mehnaj Ahmed , Pedram Razavi , Komal L. Jhaveri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1057)
DOI
10.1200/JCO.2024.42.16_suppl.1057
Abstract #
1057
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
First Author: Peter Cornelius
Poster
2023 ASCO Annual Meeting
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.
First Author: Faris Tamimi
Poster
2023 ASCO Annual Meeting
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
First Author: Stephen Chia
Poster
2023 ASCO Genitourinary Cancers Symposium
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
First Author: Adrish Sen